Month: March 2026

Adeia and UMC Expand Long-Term Collaboration in Hybrid Bonding Technologies

Written by Customer Service on March 11, 2026. Posted in Public Companies.

SAN JOSE, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Adeia Inc. (Nasdaq: ADEA), the technology company known for developing foundational innovations that enable next-generation solutions for the semiconductor and media industries, today announced that it has expanded and renewed its intellectual property (IP) licensing relationship with United Microelectronics Corporation (UMC), a leading global semiconductor foundry. The new agreement provides UMC with continued access to Adeia’s semiconductor portfolio, including hybrid bonding technologies, and extends the companies’ collaboration into future generations of 3D integration and advanced packaging solutions. “The industry is seeing growing demand for chiplet architectures, driven by AI but also across diverse applications from networking to automotive. Leveraging our partnership...

authID Partners with Section 2, Inc. to Secure “Intelligence as a Service” and Redefine Financial Crime Detection

Written by Customer Service on March 11, 2026. Posted in Public Companies.

New integration embeds biometric auditability and AI governance into Section 2’s patent-pending Hybrid Threat Finance methodology Denver, CO, March 11, 2026 (GLOBE NEWSWIRE) — authID (Nasdaq: AUID), a leading provider of biometric identity verification and AI governance solutions, today announced a strategic partnership with Section 2, Inc., a pioneer in financial threat intelligence. The collaboration integrates authID’s biometric identity platform and Mandate governance framework for Agentic AI into Section 2’s core solutions, TENet and TRACC, securing the delivery of their “Intelligence as a Service” for financial organizations with cryptographic identity assurance and full auditability. Section 2’s TENet and TRACC solutions generate sensitive intelligence and risk mappings that transform how financial institutions detect and...

CoreCivic Announces Reopening Of Midwest Regional Reception Center

Written by Customer Service on March 11, 2026. Posted in Public Companies.

BRENTWOOD, Tenn., March 11, 2026 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that it has received approval for a Special Use Permit (SUP) at the Company’s 1,033-bed Midwest Regional Reception Center in Leavenworth, Kansas. The facility has been undergoing reactivation since a new contract was awarded in the third quarter of 2025 but experienced a temporary delay in the intake process as we worked through legal challenges and the SUP approval process. Now that the SUP has been approved, we expect to begin accepting detainees at the Midwest Regional Reception Center in the coming weeks. In preparation for reactivation last year, we initiated hiring efforts and attracted a strong candidate pool. We subsequently paused hiring in December 2025 while the SUP application was under review,...

Asante Gold Announces Appointment of Chief Operating Officer and Management and Board Changes

Written by Customer Service on March 11, 2026. Posted in Public Companies.

VANCOUVER, British Columbia, March 11, 2026 (GLOBE NEWSWIRE) — Asante Gold Corporation (TSX-V: ASE | GSE: ASG | OTCQX: ASGOF) (“Asante” or the “Company“) is pleased to announce the appointment of Campbell Baird as Chief Operating Officer of the Company, together with management and board changes as part of an ongoing leadership transition designed to support the Company’s next phase of operational growth. Appointment of Chief Operating Officer The Board of Directors is pleased to announce the appointment of Campbell Baird as Chief Operating Officer of Asante, effective immediately. Mr. Baird is a mining executive with more than 30 years of international operational and technical experience across exploration, development and production environments. He has held senior executive and operational roles across...

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Written by Customer Service on March 11, 2026. Posted in Earnings Releases And Operating Results.

Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026 Secured global, exclusive license to TAPI’s innovative forms of resmetirom active pharmaceutical ingredients (API) First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Positive topline results in open-label Phase 3 trial evaluating the long-term safety of denifanstat in patients with moderate to severe acne in China reported by Ascletis China’s National Medical Products Administration (NMPA) accepted Ascletis’ New Drug Application (NDA) for denifanstat for the treatment of moderate to severe acne SAN MATEO, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical...

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Written by Customer Service on March 11, 2026. Posted in Earnings Releases And Operating Results.

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million Remaining Performance Obligations Increased 43% to Approximately $70 Million Issuing 2026 Guidance: Expecting Revenue of $66 – $68 million (27% – 30% Growth), Operating Income of 13% – 14%, and Adjusted EBITDA of $12 – $14 Million (86% – 100% Growth) Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive...

Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

Written by Customer Service on March 11, 2026. Posted in Public Companies.

Company Also Announces New Name: Quantum Cyber and Change in Nasdaq Ticker symbol BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Mr. Liscouski and the change of Company name will become effective at the Company’s extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on March 12, 2026. Mr. Liscouski is a frequent contributor to CNBC,...

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates

Written by Customer Service on March 11, 2026. Posted in Earnings Releases And Operating Results.

Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today provided business updates and reported financial results for the fourth quarter and year ended December 31, 2025. Business Updates Strategic Financing On October 23, 2025, Minerva received $80.0 million in gross proceeds from a private placement, before deducting fees and other expenses. The financing included initial upfront funding of $80.0 million and up to an additional $80.0 million if all Tranche A warrants are exercised, subject to...

Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy

Written by Customer Service on March 11, 2026. Posted in Dividend Reports And Estimates.

Company Reports Record Revenue and Profitability for Full-Year 2025 REHOVOT, Israel and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that its Board of Directors has declared a cash dividend of $0.25 (approximately NIS 0.77) per share on the Company’s ordinary shares (totaling approximately $14.4 million). The cash dividend will be payable on April 6, 2026, to shareholders of record at the close of business on March 23, 2026. The dividend payment is made in accordance with the Company’s annual cash dividend policy newly adopted by the Board of Directors, pursuant to which the Company intends to distribute...

Press release – Progress in AFL’s initiatives towards 0% risk-weighting for its debt securities to support the financing of French local governments

Written by Customer Service on March 11, 2026. Posted in Public Companies.

Press Release11 March 2026 Progress in AFL’s initiatives towards 0% risk-weighting for its debt securities to support the financing of French local governments The draft Simplification Bill, which is due to be examined by Parliament following the municipal elections in France, includes in Article 26 an amendment to the framework governing the guarantee provided by local governments to AFL’s creditors. This legislative proposal represents a major milestone for the local government bank, which is continuing its efforts to ultimately secure 0% risk-weighting for its debt securities. The proposal is the culmination of an initiative launched by AFL several years ago in conjunction with the relevant authorities, aimed at improving the financing conditions offered to local governments. It was in this context that the ACPR reached its decision...

Month: March 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals